Akero Therapeutics Inc(AKRO)stock report

Akero Therapeutics, Inc. is a clinical-stage biotechnology company that is focused on developing and commercializing treatments for serious metabolic diseases. The Company is engaged in nonalcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. The Company’s lead product candidate, AKR-001, which the Company is developing as a treatment for patients with NASH, is an analog of fibroblast growth factor 21 (FGF21). FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body.

Market Cap:633.9M; Shares Outstanding:28.6M; Short Interest: 2.33%; Q3 2019(9/30/19): Cash 148M. Loss 15.55M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -795.28 / -236.03%
2019.3.31 -31.9 -206.14% 95.99%
2019.6.30 -7.29 94.72% 77.15%
2019.9.30 -2.66 98.88% 63.51%



Insider Transactions:

Institution Ownership:

Total institutions: 71,no change
Shares hold: 13040.1k shares. no change
shares% hold: 45.66%,no change

Analyst Ratings:

2020.01.01:内部交易披露:Akero Therapeutics持股10%以上股东、高管净卖出38.87万股
2020.12.27:内部交易披露:Akero Therapeutics持股10%以上股东净卖出4.92万股

Leave a Reply